Filter
917
Text search:
formulations
Featured
124
262
Language
Document type
509
197
112
41
15
14
11
10
3
3
1
1
Countries / Regions
57
32
29
19
17
17
16
12
11
11
11
11
10
9
9
9
8
8
8
8
8
7
7
7
7
7
7
7
6
6
5
5
4
4
4
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
300
165
64
61
32
16
15
1
Toolboxes
116
90
69
60
53
42
27
23
21
18
13
10
10
9
7
6
6
6
5
4
3
2
Recommendations for a public health approach
2010 revision
Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there
...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) increasingly occur in resource-constrained settings.
In the context of a national response to MDR- and XDR-TB, health workers in
TB clinics (in district hospitals and some accredited health centres) wil
...
The TB section of the toolkit presents selected (a) programmatic output and (b) outcome and impact indicators for TB. In addition to recommended monitoring programs and measuring the outcomes and impact of TB programs, indicators for the strengthening of health systems, strengthening of community sy
...
Preliminary version for country introduction
The content of these guidelines acknowledges that wasting and undernutrition in HIV-infected children reflect a series of failures within the health system, the home and community and not just a biological process related to virus and host interactions.
The guidelines do not cover the feeding of i
...
3rd edition!Large File 17 MB!
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s
...
